These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 30769006)
21. Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a Tong Y; Chi X; Yang W; Zhong J J Virol; 2017 Apr; 91(7):. PubMed ID: 28100619 [TBL] [Abstract][Full Text] [Related]
22. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195 [TBL] [Abstract][Full Text] [Related]
23. Screening of small-molecule compounds as inhibitors of HCV entry. Yang JP; Zhou D; Wong-Staal F Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270 [TBL] [Abstract][Full Text] [Related]
24. Entry inhibitors and future treatment of hepatitis C. Fofana I; Jilg N; Chung RT; Baumert TF Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381 [TBL] [Abstract][Full Text] [Related]
25. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Liu R; Tewari M; Kong R; Zhang R; Ingravallo P; Ralston R Antiviral Res; 2010 May; 86(2):172-9. PubMed ID: 20156485 [TBL] [Abstract][Full Text] [Related]
26. Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A. Liu X; Huang Y; Cheng M; Pan L; Si Y; Li G; Niu Y; Zhao L; Zhao J; Li X; Chen Y; Yang W J Virol; 2013 Feb; 87(3):1649-57. PubMed ID: 23175359 [TBL] [Abstract][Full Text] [Related]
28. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803 [TBL] [Abstract][Full Text] [Related]
29. A computational approach identifies two regions of Hepatitis C Virus E1 protein as interacting domains involved in viral fusion process. Bruni R; Costantino A; Tritarelli E; Marcantonio C; Ciccozzi M; Rapicetta M; El Sawaf G; Giuliani A; Ciccaglione AR BMC Struct Biol; 2009 Jul; 9():48. PubMed ID: 19640267 [TBL] [Abstract][Full Text] [Related]
30. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion. Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681 [TBL] [Abstract][Full Text] [Related]
31. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Ma CD; Imamura M; Talley DC; Rolt A; Xu X; Wang AQ; Le D; Uchida T; Osawa M; Teraoka Y; Li K; Hu X; Park SB; Chalasani N; Irvin PH; Dulcey AE; Southall N; Marugan JJ; Hu Z; Chayama K; Frankowski KJ; Liang TJ Nat Microbiol; 2020 Dec; 5(12):1532-1541. PubMed ID: 32868923 [TBL] [Abstract][Full Text] [Related]
32. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Chamoun-Emanuelli AM; Pecheur EI; Simeon RL; Huang D; Cremer PS; Chen Z Antimicrob Agents Chemother; 2013 Jun; 57(6):2571-81. PubMed ID: 23529728 [TBL] [Abstract][Full Text] [Related]
33. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Halfon P; Sarrazin C Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577 [TBL] [Abstract][Full Text] [Related]
34. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788 [TBL] [Abstract][Full Text] [Related]
35. Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors. Bhat R; Adam AT; Lee JJ; Deloison G; Rouillé Y; Séron K; Rotella DP Bioorg Med Chem Lett; 2014 Sep; 24(17):4162-5. PubMed ID: 25103601 [TBL] [Abstract][Full Text] [Related]
36. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro. Hang X; Peng H; Song H; Qi Z; Miao X; Xu W J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793 [TBL] [Abstract][Full Text] [Related]
38. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry. Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693 [TBL] [Abstract][Full Text] [Related]
39. Flunarizine arrests hepatitis C virus membrane fusion. Prigozhin DM; Modis Y Hepatology; 2016 Jan; 63(1):14-6. PubMed ID: 26389725 [No Abstract] [Full Text] [Related]